A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission

Archives of Medical Science

Volumn 4, Issue 2, 2008, Pages 185-190

  Rahimi, Roja ^a   Nikfar, Shekoufeh ^b   Rezaie, Ali ^c   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Maintaining remission; Mesalazine; Meta analysis; Probiotics; Relapse; Ulcerative colitis

Indexed keywords

AZATHIOPRINE DERIVATIVE; GLUCOCORTICOID; MESALAZINE; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; STEROID;

ARTICLE; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG EFFICACY; EMBASE; ENTEROCOCCUS FAECALIS; HUMAN; INFORMATION RETRIEVAL; LACTOBACILLUS ACIDOPHILUS; MEDLINE; META ANALYSIS; RELAPSE; REMISSION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 48249089620     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004; 38: 741-5.
2. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12 (Suppl 1): S3-9.
3. Andus T, Gross V. Etiology and pathophysiology of inflammatory bowel disease-environmental factors. Hepatogastroenterology 2000; 47: 29-43.
4. Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996; 43: 381-93.
5. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-21.
6. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004; 49: 1752-7.
7. Gionchetti P, Rizzello F, Campieri M. Probiotics and antibiotics in inflammatory bowel disease. Curr Opin Gastroenterol 2001; 17: 331-5.
8. Mach T. Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol 2006; 57 (Suppl 9): 23-33.
9. Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 2006; 8: 486-98.
10. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007; 52: 2920-5.
11. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28: 1983-8.
12. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008; 53: 1278-84.
13. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008 [Epub ahead of print].
14. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-74.
15. Gionchetti P, Rizzello F, Habal F, et al. Standard treatment of ulcerative colitis. Dig Dis 2003; 21: 157-67.
16. Moum B. 5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease. Tidsskr Nor Laegeforen 2003; 123: 2565-7.
17. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2002; 22: 56-63.
18. Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10: 1521-5.
19. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-8.
20. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-9.
21. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-23.
22. Sheil B, Shanahan F, O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr 2007; 137 (3 Suppl 2): 819S-24S.
23. Rioux KP, Madsen KL, Fedorak RN. The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol Clin North Am 2005; 34: 465-82.
24. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006; 55: 1141-9.
25. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 106-11.
26. Biancone L, Tosti C, Fina D, et al. Review article: maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 2003; 17 (Suppl 2): 31-7.
27. Jones JL, Foxx-Orenstein AE. The role of probiotics in inflammatory bowel disease. Dig Dis Sci 2007; 52: 607-11.
28. Gionchetti P, Rizzello F, Campieri M. Probiotics in gastroenterology. Curr Opin Gastroenterol 2002; 18: 235-9.